Tripentadecanoin for Use in Treatment of Retinal or Optic Nerve Degenerative Disease

EPO published patent EP3468551A1 granting SunRegen Healthcare AG intellectual property protection for tripentadecanoin as a therapeutic agent for retinal degenerative disease or optic nerve degenerative disease. The patent covers the specific medical use claim and names three inventors. The designated contracting states include all major European markets (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).

Competitors developing therapies for retinal or optic nerve degenerative conditions should conduct freedom-to-operate analyses to assess whether their technologies infringe this patent. Pharmaceutical companies and healthcare providers involved in ophthalmic therapeutics should monitor this IP development for potential licensing considerations or alternative formulation strategies.